Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants - Scorecard - MDSpire

Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

  • By

  • Ilker Nihat Ökten

  • Tuba Baydaş

  • Sinan Koca

  • Mukaddes Feyza Baltacı

  • Filiz Özen

  • İbrahim Çil

  • Metin Eser

  • Adnan Gündoğdu

  • Merve Aktaş

  • Osman Cem Yılmaz

  • February 13, 2026

  • 0 min

Share

Clinical Scorecard: Surgical Outcomes for Breast Cancer Amid Genetic Ambiguity: Insights on BRCA1/2 Pathogenic Variants and Uncertain Significance Variants

At a Glance

CategoryDetail
ConditionBreast Cancer
Key MechanismsGermline pathogenic variants in BRCA1/2 increase breast and ovarian cancer risk; VUS pose challenges in clinical decision-making.
Target PopulationFemale patients diagnosed with breast cancer carrying BRCA1/2 variants or VUS.
Care SettingMulticenter study conducted in tertiary public hospitals and private oncology clinics in Türkiye.

Key Highlights

  • Over 2.3 million new breast cancer cases globally in 2022.
  • Pathogenic BRCA variants confer a 45%-75% lifetime breast cancer risk.
  • VUS in BRCA1/2 complicate clinical management decisions.
  • Study included 203 patients with BRCA variants or VUS.
  • Surgical management patterns differ between pathogenic variant and VUS carriers.

Guideline-Based Recommendations

Diagnosis

  • Germline BRCA1/2 testing recommended for breast cancer patients.

Management

  • Clinical management decisions should not be based solely on VUS presence.

Monitoring & Follow-up

  • Intensified screening and risk-reducing surgery considered for pathogenic variant carriers.

Risks

  • Pathogenic BRCA variants significantly increase cancer risk; VUS may lead to uncertainty in management.

Patient & Prescribing Data

Female breast cancer patients with BRCA1/2 variants or VUS.

Surgical decisions may be influenced by the ambiguity surrounding VUS.

Clinical Best Practices

  • Utilize updated genetic testing guidelines for variant classification.
  • Consider family history in risk assessment and management planning.
  • Engage in shared decision-making with patients regarding surgical options.

References

Original Source(s)

Related Content